- Home
- GDEV vs ACOG Comparison
GDEV vs ACOG Comparison
Compare GDEV & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GDEV | ACOG |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | Cyprus | Canada |
| Employees | 475 | 71 |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.1M | 185.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GDEV | ACOG |
|---|---|---|
| Price | $12.60 | $7.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 4.9K | ★ 92.2K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.56 | $139.22 |
| Revenue Next Year | $8.05 | $134.48 |
| P/E Ratio | $5.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.20 | $4.50 |
| 52 Week High | $42.20 | $10.14 |
Technical Indicators
Market Signals| Indicator | GDEV | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 49.76 | 56.70 |
| Support Level | $11.64 | $5.27 |
| Resistance Level | $18.24 | $8.80 |
| Average True Range (ATR) | 0.87 | 0.56 |
| MACD | 0.09 | -0.08 |
| Stochastic Oscillator | 19.52 | 40.74 |
Price Performance
Historical ComparisonAbout GDEV GDEV Inc.
GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.
About ACOG Alpha Cognition Inc.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.